PAVM — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-13

• The Company’s cost of revenue from subscription revenue was derived from its Veris Health Cancer Care Platform. We have incurred expenses associated with the platform in the period in which the activities occur.

• approximately $1.2 million increase related to cash and stock-based compensation costs; and

• approximately $0.2 million decrease related to third-party professional fees, primarily due to financing-related costs.

• In the three months ended June 30, 2026, research and development costs were approximately $2.1 million, as compared to $0.8 million for the corresponding period in the prior year. The net increase of $1.3 million principally related to the research and development costs incurred at Veris for the im…

• The three months ended June 30, 2026 as compared to the three months ended June 30, 2025 - continued

Text removed vs the prior filing · source: 10-Q · 2026-05-14

• the risk that the FDA will cease to exercise enforcement discretion with respect to LDTs, like EsoGuard;

• In December 2025, Lucid announced results from an 18-month real-world experience evaluating EsoGuard and EsoCheck in approximately 12,000 patients. The analysis demonstrated high technical success rates, rapid procedure times, and appropriate physician utilization in routine clinical practice, consi…

• At a special meeting of the Company’s stockholders held on December 5, 2025, the Company’s stockholders approved a reverse stock split of the Company’s outstanding shares of common stock (the “Reverse Split”) at a specific ratio, ranging from 1-for-10 to 1-for-30, to be determined by the Company’s b…

• Following the special meeting, the Board approved a ratio of 1-for-30 for the Reverse Split. On December 30, 2025, in order to effect the Reverse Split and the Reduction in Authorized Common Stock, the Company filed a certificate of amendment to its certificate of incorporation, as amended, pursuant…

• The purpose of the Reverse Split was to help the Company regain compliance with the $1 minimum bid requirement for continued listing on the Capital Market of the Nasdaq Stock Market LLC ("Nasdaq"), which it did, as discussed below. All shares and per share amounts set forth herein give effect to the…

Text added vs the prior filing · source: 10-Q · 2026-08-13

• Effective as of June 30, 2026, the Company and the Holder agreed to amend the Minimum Cash Covenant under the 2026 Note to provide that the amount of the Company’s available cash will equal or exceed $2.5 million as of each Measurement Date (or, for any Measurement Date on or after September 15, 202…

• During the fiscal quarter ended June 30, 2026, none of our directors or officers (as defined in Rule 16a-1 under the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (as those terms are defined in Item 408 of Regulation S-K).

Text removed vs the prior filing · source: 10-Q · 2026-05-14

• During the fiscal quarter ended March 31, 2026, none of our directors or officers (as defined in Rule 16a-1 under the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (as those terms are defined in Item 408 of Regulation S-K).